Arvinas (NASDAQ:ARVN) Shares Up 9.9% - What's Next?

Key Points

• Shares rose 9.9% on Friday to about $10.88 on unusually light trading (≈222k shares vs. a ~810k average).
• Earnings and revenue missed sharply: Arvinas reported Q results of $(1.10) EPS vs. $(0.55) expected and revenue of $9.5M vs. $37.3M expected, with revenue down ~84% year‑over‑year and negative margins.
• Mixed analyst and insider signals: the consensus rating is "Hold" with an average price target of $13.88, while a director purchased 20,000 shares at $13.40 even as insiders sold shares overall.

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report)'s stock price shot up 9.9% on Friday . The stock traded as high as $10.33 and last traded at $10.8810. 222,458 shares were traded during trading, a decline of 73% from the average session volume of 810,316 shares. The stock had previously closed at $9.90.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ARVN. BTIG Research boosted their price objective on Arvinas from $14.00 to $16.00 and gave the stock a "buy" rating in a report on Thursday, March 19th. Weiss Ratings reissued a "sell (d-)" rating on shares of Arvinas in a report on Friday, April 10th. Wedbush boosted their price objective on Arvinas from $9.00 to $11.00 and gave the stock a "neutral" rating in a report on Tuesday, February 24th. Piper Sandler reissued an "overweight" rating and set a $20.00 price objective (up from $16.00) on shares of Arvinas in a report on Wednesday, February 25th. Finally, Zacks Research cut Arvinas from a "hold" rating to a "strong sell" rating in a report on Monday. Ten equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $13.88.

Arvinas Trading Up 6.2%

The company has a market capitalization of $672.22 million, a P/E ratio of -8.21 and a beta of 1.97. The business has a 50 day moving average price of $11.54 and a 200 day moving average price of $11.63.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($1.10) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.55). The company had revenue of $9.50 million during the quarter, compared to the consensus estimate of $37.26 million. Arvinas had a negative net margin of 30.77% and a negative return on equity of 14.25%. The business's revenue was down 84.0% compared to the same quarter last year. During the same period last year, the company earned ($0.63) earnings per share. On average, analysts forecast that Arvinas, Inc. will post -3.26 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Briggs Morrison purchased 20,000 shares of the stock in a transaction dated Friday, March 6th. The stock was bought at an average cost of $13.40 per share, with a total value of $268,000.00. Following the purchase, the director directly owned 96,021 shares in the company, valued at $1,286,681.40. The trade was a 26.31% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Andrew Saik sold 5,134 shares of the company's stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $11.89, for a total value of $61,043.26. Following the completion of the sale, the chief financial officer directly owned 159,267 shares of the company's stock, valued at approximately $1,893,684.63. This trade represents a 3.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 63,864 shares of company stock worth $802,443 over the last quarter. Insiders own 4.73% of the company's stock.

Institutional Trading of Arvinas

A number of large investors have recently bought and sold shares of ARVN. ProShare Advisors LLC grew its position in Arvinas by 7.2% in the fourth quarter. ProShare Advisors LLC now owns 14,827 shares of the company's stock valued at $176,000 after acquiring an additional 993 shares during the last quarter. Intech Investment Management LLC grew its position in Arvinas by 3.6% in the third quarter. Intech Investment Management LLC now owns 32,653 shares of the company's stock valued at $278,000 after acquiring an additional 1,125 shares during the last quarter. MetLife Investment Management LLC grew its position in Arvinas by 4.3% in the fourth quarter. MetLife Investment Management LLC now owns 33,810 shares of the company's stock valued at $401,000 after acquiring an additional 1,381 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Arvinas by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company's stock valued at $271,000 after acquiring an additional 2,122 shares during the last quarter. Finally, Oxford Asset Management LLP grew its position in Arvinas by 15.5% in the second quarter. Oxford Asset Management LLP now owns 16,705 shares of the company's stock valued at $123,000 after acquiring an additional 2,242 shares during the last quarter. 95.19% of the stock is owned by institutional investors.

About Arvinas

Arvinas, Inc NASDAQ: ARVN is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body's natural protein-recycling systems.

The company's most advanced clinical candidates address hormone-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.